News Story: Full Text
Sponsored By
Gleolan for brain tumors
Please Click On The Above Banner For More Details
Braintumor Website

 

MATEON THERAPEUTICS TEAM PUBLISHES A NEW PEER-REVIEWED ONCOLOGY ARTICLE ON THE POSITIVE CLINICAL STUDY RESULTS FOR OT-101 AGAINST RECALCITRANT RESISTANT ANAPLASTIC ASTROCYTOMA – A RARE FORM OF MALIGNANT BRAIN TUMOR

Al's Comment:

     They reported a huge improvement in median overall survival for recurrent / recalcitrant Anaplastic Astrocytoma. 1,136 days for this experimental treatment compared to 590 days for the standard Temozolomide. That is more than double.    This is given by convection enhanced delivery. This drug is a new TGF-Beta antisense drug.   It should theoretically work for a wide variety of cancers and is also being studied for use against the COVID-19 virus.  


Posted on: 04/03/2020

MATEON THERAPEUTICS TEAM PUBLISHES A NEW PEER-REVIEWED ONCOLOGY ARTICLE ON THE POSITIVE CLINICAL STUDY RESULTS FOR OT-101 AGAINST RECALCITRANT RESISTANT ANAPLASTIC ASTROCYTOMA – A RARE FORM OF MALIGNANT BRAIN TUMOR

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740